- Pivotal clinical validation data for Percepta
Nasal Swab test in early lung cancer detection -
- New data demonstrating ability of Decipher
Prostate test to identify high metastasis risk in African American
men -
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics
company with a presence in seven of the top ten cancers in the
United States, announced today that six abstracts for its genomic
tests in lung, prostate and thyroid cancers will be presented at
the 2021 ASCO Annual Meeting, which will be held virtually June
4-8, 2021.
The accepted abstracts include pivotal clinical validation data
for Veracyte’s Percepta Nasal Swab. This first-of-its-kind,
non-invasive test will help physicians determine which patients
with lung nodules found on CT scans are at low risk for cancer and
can be safely directed to routine monitoring without fear of
missing a cancer and which patients should undergo further,
including potentially more-aggressive, clinical work-up. Veracyte
plans to introduce the nasal swab-based genomic test in the second
half of 2021, as part of the company’s comprehensive lung cancer
portfolio.
“We are thrilled with the compelling data that will be presented
at ASCO, which reflect our tests’ ability to positively impact
patient care in a range of major cancers,” said Bonnie Anderson,
Veracyte’s chairman and chief executive officer. “We are
particularly excited about the opportunity in lung cancer, where
early detection can save lives, but where distinguishing between
cancerous and benign lung nodules is often challenging and can lead
to missed cancers or unnecessary procedures. We believe our
Percepta Nasal Swab test is going to be a game-changer for patients
being evaluated for lung cancer.”
Among other Veracyte highlights, researchers will share
prospective validation data for the Decipher Prostate test,
demonstrating the genomic test’s ability to predict aggressive
prostate cancers among African American men as compared to the use
of clinical factors alone.
Below are details of the Veracyte abstracts accepted for
presentation at ASCO. All posters will be available to meeting
registrants on demand beginning June 4, 2021, at 9:00 a.m. EDT.
Title:
Early candidate nasal swab classifiers
developed using machine learning and whole transcriptome sequencing
may improve early lung cancer detection.
(Title of poster to be presented: A
validated nasal swab classifier developed using machine learning
and whole transcriptome sequencing may improve early lung cancer
detection.)
Abstract #:
8551
First Author:
Peter Mazzone, M.D., M.P.H., Cleveland
Clinic
Title:
A prospective Validation of the genomic
classifier defines high-metastasis risk in a subset of African
American men with early localized prostate cancer: VanDAAM study.
(oral presentation)
Abstract #:
5005
First Author:
Kosj Yamoah, M.D., Ph.D., Moffitt Cancer
Center
Time:
June 8, 2021, 8:00-11:00 a.m. EDT
Title:
The impact of Percepta Genomic Sequencing
Classifier (GSC) on clinical decision making in patients with a
high- risk lung nodule. (poster presentation)
Abstract #:
8549
First Author:
Sonali Sethi, M.D., Cleveland Clinic
Title:
Validation of the Decipher Genomic
Classifier (GC) in SAKK 09/10: A Phase III Randomized Trial of
Dose-Escalated Salvage Radiotherapy (SRT) after Radical
Prostatectomy (RP). (poster presentation)
Abstract #:
5010
First Author:
Alan Dal Pra, M.D., University of Miami
Health System
Title:
NTRK, RET, BRAF, and ALK Fusions in
Thyroid Fine-Needle Aspirates (FNAs). (poster presentation)
Abstract #:
6083
First Author:
Lori J. Wirth, M.D., Massachusetts General
Hospital
Title:
Detection of actionable molecular
alterations through combined DNA/RNA molecular profiling of
biopsies collected in early stage lung cancer at time of diagnosis.
(online abstract)
Abstract #:
e20546
First Author:
Joshua Babiarz, Ph.D., Veracyte
About Veracyte
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company
that improves patient care by providing answers to clinical
questions, informing diagnosis and treatment decisions throughout
the patient journey in cancer and other diseases. The company’s
growing menu of genomic tests leverage advances in genomic science
and technology, enabling patients to avoid risky, costly diagnostic
procedures and quicken time to appropriate treatment. The company’s
tests in lung cancer, prostate cancer, breast cancer, thyroid
cancer, bladder cancer and idiopathic pulmonary fibrosis are
available to patients and its lymphoma subtyping and renal cancer
tests are in development. With Veracyte’s exclusive global license
to a best-in-class diagnostics instrument platform, the company is
positioned to deliver its tests to patients worldwide. Veracyte is
based in South San Francisco, California. For more information,
please visit www.veracyte.com and follow the company on Twitter
(@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to the Percepta Nasal Swab and our Decipher prostate
and Veracyte thyroid tests. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan,"
"expect," "believe," "should," “suggest,” "may," "will"
“prospective” and similar references to future periods. Actual
results may differ materially from those projected or suggested in
any forward-looking statements. Examples of forward-looking
statements include, among others, statements regarding Veracyte’s
belief that its Percepta Genomic Atlas Nasal Swab and our Envisia
Decipher prostate and Veracyte thyroid tests provide clinical value
that helps physicians diagnose and treat lung cancer. Additional
factors that may impact these forward-looking statements can be
found under the caption “Risk Factors” in our Annual Report on Form
10-K filed with the SEC on February 22, 2021 and our subsequent
quarterly reports on Form 10-Q. A copy of these documents can be
found at the Investors section of our website at www.veracyte.com.
The risks and uncertainties may be amplified by the COVID-19
pandemic, which has caused significant economic uncertainty. The
extent to which the COVID-19 pandemic impacts Veracyte’s
businesses, operations, and financial results, including the
duration and magnitude of such effects, will depend on numerous
factors, which are unpredictable, including, but not limited to,
the duration and spread of the outbreak, its severity, the actions
to contain the virus or treat its impact, and how quickly and to
what extent normal economic and operating conditions can resume.
These forward-looking statements speak only as of the date hereof
and, except as required by law, Veracyte specifically disclaims any
obligation to update these forward-looking statements or reasons
why actual results might differ, whether as a result of new
information, future events or otherwise.
Veracyte, Afirma, Percepta, Envisia, Prosigna, "Know by Design"
and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are
registered trademarks of Veracyte in the U.S. and selected
countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005432/en/
Tracy Morris Vice President of Corporate Communications &
Investor Relations tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From May 2023 to May 2024